Sign inJoin waitlistJoin the waitlist

Lea Baer

Assistant Professor of Medicine · Stony Brook Medicine

Credentials: · · · ·

History

Stony Brook Medicine
Present

Hematology and Medical Oncology
2002–2005
Internal Medicine
1999–2002
Doctor of Medicine
1995–1999

Research

Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging
Review · Circulation Heart Failure · 2016 · 274 citations
Bevacizumab increases risk for severe proteinuria in cancer patients
Systematic review or meta-analysis · Journal of the American Society of Nephrology · 2010 · 194 citations
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal…
Journal of Clinical Oncology · 2023 · 183 citations

Jules Cohen
5 papers
Alison Stopeck
4 papers
Hal Skopicki
3 papers
Javed Butler
3 papers
Anju Nohria
2 papers
Bonnie Ky
2 papers
Carine Hamo
2 papers · 2 as a resident
DL
Daniel Lenihan
2 papers
Julie Gemmill
2 papers · 1 as a fellow
Kevin Kalinsky
2 papers
MG
Mihai Gheorghiade
2 papers
Aditi Bhagat
1 paper · 1 as a fellow

Clinical trials

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
Principal investigator · Withdrawn · Early phase 1
Alison Stopeck
2019–2020
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Site PI · Recruiting · Phase 2
Biostar Pharma, Inc.
2025–2027
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Site PI · Recruiting · Phase 3
Stemline Therapeutics, Inc.
2024–2032